Positive Results Announced for Enzyme Replacement Therapy

August 11, 2008

An investigational enzyme replacement therapy called Trizytek was shown to improve fat absorption in cystic fibrosis patients during a Phase 3 trial, Altus Pharmaceuticals, Inc. announced today. The CF Foundation and Altus have worked to develop this porcine-free product since 2002. Detailed results will be presented at the 2008 North American Cystic Fibrosis Conference.

“We are very encouraged by the Trizytek efficacy data because this treatment will offer important new benefits to CF patients who need enzyme replacement therapy,” said Robert J. Beall, Ph.D., president and CEO of the CF Foundation. “Currently, the dosing regimens for enzymes can be a challenge for patients. The one capsule per meal dosing for Trizytek will help drive better compliance and therefore enhance long-term patient health outcomes.”

Read the full release.